摘要
CRO由20世纪70年代诞生以来,经过20多年的迅猛发展,已经在药物研发领域替代了传统的学术角色,据统计,2000年全球有40%的制药企业将其全部或部分研发业务外包。然而,当前的制药企业普遍缺乏对药物研发外包行为风险的认识及评估,本文借鉴Bahli的理论,对药物研发外包行为的风险因素做出详尽的分析,以期丰富对药物研发外包行为的风险管理理论。
Once come into being from 70 years of twenty century CRO had already substituted the position of traditional academic though a rapid development for 20 years. According to a study, about 40% pharmaeeutieal manufacturers chose to outsouree their part or whole R&D work in :2000. However, the risks for Pharmaceutical R&D Outsourcing were rarely mentioned. Drawing on the experience of Bahli's work, this article has analyze the risk factors of Pharmaceutical R&D Outsourcing, as to enrich the risk management theory for Pharmaceutical R&D Outsourcing.
出处
《中国民族民间医药》
2010年第7期76-77,共2页
Chinese Journal of Ethnomedicine and Ethnopharmacy